Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #98071 on Biotech Values
genisi
01/11/11 2:49 AM
#112282 RE: mcbio #98071
$250 million cash payment upon certain U.S. approval of ABRAXANE® by FDA for NSCLC with progression-free survival claim in U.S. label
Completed Interim Analysis of ABRAXANE(R) Phase III Study in Non-Small Cell Lung Cancer (NSCLC); Interim Analysis of Progression Free Survival (PFS) in the Intent-to-Treat Population, While Not Statistically Significant, Supports Submission of a Supplemental New Drug Application for the Treatment of Advanced NSCLC During the Second Half of 2011. Final Analysis, Including Subset Analyses, Expected to Be Completed and Presented During an Upcoming Medical Meeting.